Evidence Hub

CYP2C19 Loss‐of‐Function Is an Independent Risk Factor of Coronary Artery Disease in Patients With Hypertension

Guoliang Wei, Bin Li, Hao Wang, Wenhao Chen, Kehui Chen, Weihong Wang, Shen Wang, Hui Zeng et al.

Journal of Clinical Laboratory Analysis, 2025

3,404 participants · 1 citation

Abstract

ABSTRACT Objective Cytochrome P450 2C19 (CYP2C19) is affected by its gene polymorphisms and is involved in the occurrence and development of diseases. To assess the relationship between CYP2C19 polymorphisms and coronary artery disease (CAD) susceptibility in hypertensive patients. Methods This study retrospectively analyzed 3404 hypertensive patients who were admitted to Meizhou People's Hospital from November 2019 to August 2023, including 1438 CAD patients and 1966 nonCAD individuals. The CYP2C19 rs4244285 (681G>A, *2) and rs4986893 (636G>A, *3) polymorphisms were genotyped by polymerase chain reaction (PCR)‐chip technique. The relationship between CYP2C19 polymorphisms and CAD was analyzed. Results There were 1567 (46.0%), 1491 (43.8%), and 346 (10.2%) individuals with CYP2C19 extensive metabolizer (EM) (CYP2C19*1/*1), intermediate metabolizer (IM) (CYP2C19*1/*2 and *1/*3), and poor metabolizer (PM) (CYP2C19*2/*2, *2/*3, and *3/*3) phenotype. The CAD patients had higher frequencies of the *2 allele (30.2% vs. 26.0%, p < 0.001), *3 allele (4.9% vs. 3.8%, p = 0.021) and lower frequency of *1 allele (64.8% vs. 70.2%, p < 0.001) than controls. Logistic regression analysis showed that body mass index (BMI) ≥ 24.0 kg/m2 (odds ratio (OR): 1.364, 95% confidence interval (CI): 1.184–1.571, p < 0.001), history of alcoholism (OR: 1.761 95% CI: 1.211–2.559, p = 0.003), and CYP2C19 IM + PM phenotypes (IM + PM vs. EM, OR: 1.314, 95% CI: 1.145–1.508, p < 0.001) were independent risk…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free